Drugs and Devices

FDA approves Zykadia for NSCLC

On April 29, the U.S. Food and Drug Administration (FDA) approved Zykadia for patients with a certain type of late-stage non-small cell lung cancer (NSCLC). Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares